Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12AZY | ISIN: SE0005497732 | Ticker-Symbol: 7JK
Frankfurt
21.11.24
15:29 Uhr
5,600 Euro
+0,080
+1,45 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EQL PHARMA AB Chart 1 Jahr
5-Tage-Chart
EQL PHARMA AB 5-Tage-Chart

Aktuelle News zur EQL PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEQL Pharma's CBDO increases his holding in the company1
06.11.EQL Pharma AB: Interim Report April - September 20242Sales and operating profit growth, new products added to the pipeline July - September 2024 Consolidated sales during the second quarter, July to September amounted to SEK 85.2 (59.6) million, an...
► Artikel lesen
25.10.Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2024/25-
19.08.EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 19 August 202461Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below. Resolution on adoption of accounts and allocation of the company's...
► Artikel lesen
08.08.EQL Pharma AB: Interim Report April - June 202464Sales and operating profit growth, new products added to the pipeline April - June Consolidated sales during the first quarter, April to June amounted to SEK 82.8 (56.2) million, an increase of 47%....
► Artikel lesen
16.07.Notice of annual general meeting in EQL Pharma AB1
EQL PHARMA Aktie jetzt für 0€ handeln
15.07.Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2024/251
05.07.EQL PHARMA: Mellozzan[® ](melatonin) has gained marketing approval in Switzerland1
04.07.Nasdaq Stockholm welcomes EQL Pharma to the Main Market201Stockholm, Jul 4, 2024 - Nasdaq (Nasdaq: NDAQ) announces that trading in the shares of EQL Pharma AB (ticker name: EQL) will commence today on the Nasdaq Stockholm Main Market. EQL Pharma is a Small...
► Artikel lesen
04.07.Trading in EQL Pharma's shares on Nasdaq Stockholm commences today2
02.07.Nasdaq Stockholm AB: Listing of EQL Pharma AB on Nasdaq Stockholm186On request of EQL Pharma AB, company registration number 556713-3425, Nasdaq Stockholm has admitted the company's shares to trading with effect from July 4, 2024. As per today's date the company has...
► Artikel lesen
28.06.EQL Pharma AB publishes prospectus for list change to Nasdaq Stockholm1
28.06.Spotlight Stock Market: Market Notice 138/24 - EQL Pharma AB will be delisted after close of the market on July 3, 20241
27.06.Nasdaq Stockholm AB: Listing of EQL Pharma AB on Nasdaq Stockholm181Nasdaq Stockholm AB has assessed that EQL Pharma AB, company registration number 556713-3425, fulfills Nasdaq Stockholm's listing requirements. Provided that EQL Pharma AB applies for admission to trading...
► Artikel lesen
12.06.EQL Pharma AB has been approved for listing on Nasdaq Stockholm1
27.05.EQL Pharma's CEO increases his holding in the company1
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1